Tranzyme Pharma (TZYM) to Present at the Canaccord Genuity 32nd Annual Growth Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 1, 2012 (GLOBE NEWSWIRE) — Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and CEO, and Richard I. Eisenstadt, Vice President, Finance and CFO, will present at the Canaccord Genuity 32^nd Annual Growth Conference taking place at the Intercontinental Hotel in Boston, MA August 14-16, 2012. Tranzyme’s presentation is scheduled for Tuesday, August 14^th at 1:00 pm ET in the Vancouver Room followed by a breakout session.

A live audio webcast of the presentation will be available in the “Investors” section of the Tranzyme Pharma website, www.tranzyme.com, following the conference.

About Tranzyme Pharma

Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. Enrollment in a multinational Phase 2b trial evaluating TZP-102 in diabetic patients with gastroparesis is ongoing; top-line data are expected by year-end 2012. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company’s web site at www.tranzyme.com.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com

         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com